Physician profile
Reena Mehra
NPI 1578583290
$36,060.69
in general payments reported to CMS, 2019-2025
12 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2022: $272 · 2023: $4,402 · 2024: $13K · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $2,517 · Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,314.00 |
| Travel and Lodging | $2,517.37 |
| Food and Beverage | $1,365.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12,853.50 | 2024 | Zepbound |
| Merck Sharp & Dohme LLC | $11,498.35 | 2019 | |
| Zoll Respicardia, INC. | $5,301.07 | 2019-2024 | Remede System |
| Eli Lilly and Company | $4,000.00 | 2023 | |
| Amgen INC. | $1,314.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $560.72 | 2019-2025 | |
| Intuitive Surgical, INC. | $238.46 | 2022-2023 | |
| Boston Scientific Corporation | $125.28 | 2022 | |
| Body Vision Medical INC. | $111.31 | 2024 | Lungvision |
| Visionair Solutions, LLC | $58.00 | 2025 | Visionair Patient Specific Airway Stent |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.